Results for tag: "Pegloticase"

Pegloticase is a biologic drug used to treat chronic gout, a type of immune disorder. It is a recombinant form of the enzyme uricase, which breaks down uric acid in the body. Pegloticase is administered intravenously and works by reducing the levels of uric acid in the blood, which helps to reduce inflammation and pain associated with gout. It is approved by the US Food and Drug Administration (FDA) for use in adults who have not responded to conventional therapies. Pegloticase is a relatively new drug and is still in the early stages of development. It is currently only available in the US, but is being studied in other countries. The drug is expensive and is not covered by most insurance plans. The market for pegloticase is expected to grow in the coming years as more people are diagnosed with gout and as the drug is approved for use in other countries. Companies in the pegloticase market include Savient Pharmaceuticals, Horizon Pharma, and Ardea Biosciences. Show Less Read more